Skip to content

Author

Xiangsheng Liu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Use of a c-Met-targeting aptamer-drug conjugate for efficient therapy in both primary and metastatic uveal melanoma.

Uveal melanoma (UM), the most common primary intraocular malignancy in adults, is associated with a high risk of metastasis, recurrence, and irreversible vision loss. However, current therapeutic options remain limited by insufficient efficacy and poor vision preservation. Building upon the molecular design of SL1-MMAE...

Zhao-Qi Pan, Jia-Xuan He, Si-Yu Dong et al. · 0 citations
Oct 2026

Reprogramming tumor-associated macrophages via ID3 mRNA delivery for enhanced immunotherapy in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) features a profoundly immunosuppressive tumor microenvironment dominated by tumor-associated macrophages (TAMs), which facilitate immune evasion and compromise immunotherapeutic efficacy. The interaction between signal regulatory protein α (SIRPα) on macrophages and cluster of di...

Wen-Jing Zhou, Hao-Yang Wang, Yu-Ting Li et al. · 0 citations
Open access Sep 2026

Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy

Summary c-Met overexpression promotes tumor progression in many cancers, yet approved inhibitors benefit only patients with MET mutation, leaving most c-Met-overexpressing patients without effective therapy. Inspired by antibody-drug conjugates (ADCs), composed of an antibody linked to cytotoxic agents, a c-Met-targeti...

Yuan Liu, Jia-Xuan He, Minhui Su et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.